Join our daily newsletter At The Bell to receive exclusive market insights
- Zelira Therapeutics (ZLD) reports testing of its oral cannabidiol (CBD) capsules on mice with neurological diseases has proved successful
- The biopharmaceutical company says the results show improved delivery of CBD into the brain by up to 40-times
- ZLD funded the study by Curtin University Researchers, with the mice trial and results set to be published in peer-reviewed journal PLOS ONE
- Next steps for Zelira will be to commence human studies using the CBD capsules, which aim to help treat neurological disorders
- Company shares are up 3.19 per cent at 4.9 cents each
Zelira Therapeutics (ZLD) reports testing of its oral cannabidiol (CBD) capsules on mice with neurological diseases has proved successful.
The biopharmaceutical company had teamed up with Curtin University researchers to sponsor a study on its treatment.
ZLD believes its CBD capsules could help treat a range of neurological disorders including Alzheimer’s disease, multiple sclerosis and traumatic brain injuries.
Pleasingly, the company said the results from this latest study show improved delivery of CBD into the brain by up to 40-times.
Lead researcher Associate Professor Ryu Takechi explained the findings could be helpful in supporting the clinical use of medicinal cannabis.
“CBD is found in medicinal cannabis and is a popular natural remedy for people living with neurological and metabolic diseases,” Associate Professor Takechi said.
“In an effort to address the issue of limitations in the absorption of cannabidiol, we aimed to design and test a new drug delivery method.
“The findings may be helpful in supporting the clinical use of medicinal
cannabis in the treatment of neurological disorders.”
The fast-penetration result and wider mice study will be published in peer-reviewed journal PLOS ONE.
Zelira will also begin exploring the possibility of commencing human studies using the CBD capsules.
“The new encapsulation technology significantly improves the efficiency with which cannabinoid-based drugs can be delivered into the brain and presents a game-changing platform to improve the effectiveness of cannabinoid therapies for neurological disorders while reducing cost and enhancing safety,” CEO Dr Oludare Odumosu said.
“This development further affirms Zelira’s commitment to innovation and leadership in cannabinoid medicine development.”
ZLD shares were up 3.19 per cent at 4.9 cents each at 1:06 pm AEST.
